QIAGEN appoints Jonathan Pratt CEO
Analysis based on 11 articles · First reported Aug 24, 2026 · Last updated Aug 24, 2026
The appointment of a new CEO with extensive industry experience is generally viewed positively, potentially stabilizing investor sentiment and supporting QIAGEN's stock. The reaffirmed outlook and ongoing strategic review may provide additional confidence, though the transition introduces some uncertainty.
On August 24, 2026, Qiagen announced the appointment of Jonathan Cran as Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of international leadership experience in life sciences, laboratory technologies, and healthcare. He previously served as President and CEO of Filtration Group, leading its sale to Parker Hannifin in August 2026, and held senior roles at Waters Corporation, Beckman Coulter (a Danaher operating company), and Danaher Corporation — Pall Corporation. Thierry Bernard will step down as CEO and Managing Director, supporting an orderly transition through the end of the year. Pratt will be proposed for shareholder approval as a Managing Director at an Extraordinary General Meeting planned for Q4 2026. QIAGEN reaffirmed its Q3 and full-year 2026 outlook and continues its strategic review to create shareholder value.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard